Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38 Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingSafe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38
DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingDNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.
Cellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged. Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingCellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged.
Cellect Biotechnology Ltd.: Exposure to the global stem cells industry Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingCellect Biotechnology Ltd.: Exposure to the global stem cells industry
Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38 Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingSafe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38
Brainsway Ltd.: The Company continues to generate consistent growth based on the rental model; we assume operating balance in 2018; Capital raising reflects the confidence of institutional investors. Price target remains within the forecast range. Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBrainsway Ltd.: The Company continues to generate consistent growth based on the rental model; we assume operating balance in 2018; Capital raising reflects the confidence of institutional investors. Price target remains within the forecast range.
Brainsway Ltd.: The company continues with its lease-based model; we expect an operational balance by 2018; Credit line granted will support rapid growth. Target price unchanged. Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBrainsway Ltd.: The company continues with its lease-based model; we expect an operational balance by 2018; Credit line granted will support rapid growth. Target price unchanged.
BioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged. Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.
